Mylan Pharmaceuticals Inc. Conducting Voluntary Nationwide Recall of Insulin Injection

On April 12, 2022, Mylan Pharmaceuticals Inc. recalled one batch of insulin.

Labels were missing on one batch of Insulin Glargine Injection.

This package is an unbranded Insulin Glargine- yfgn vial and product information, batch number and expiry date information are present on the carton.

Insulin Glargine was distributed in the United States between December 9, 2021 and March 4, 2022.  Patients who received this treatment with more than one type of insulin, could have been administered the wrong strength of treatment/ mix-up of products.  This could have led the patient to have a high or low blood sugar control—which could result in serious complications.

Insulin Glargine is a long-acting human insulin that is used to improve glycemic control and could be used as treatment for adults and pediatric patients.

The company initiated this recall and have notified distributors.

Were these vials inspected prior to being released?  Is there trace of approval for these vials?

With InQuest Science’s Identifier software, we require the need for inspection and approval before a product is released to patients and retailers.  Defects and mistakes are less likely to occur when having an outlined inspection/ workflow process right at your fingertips.  Less paperwork, with a clear understanding of requirements is our goal to help your manufacturing companies succeed.

Read the full recall published by the FDA

Comments are closed.